Forty-eight hours (seventy-two hours for invasive electroporation) post electroporation, RFP expression in muscle was examined by In-Vivo Imaging System (Carestream In-Vivo Imaging System FX Pro, Carestream Health, USA). The 550 nm excitation and 600 nm emission filters were chosen for the experiment. According to the manufacture's specification, the bandpasses of such excitation and emission filters are 20 nm and 60 nm (wide angle) respectively, suggesting the excitation and emission spectrum are 540–560 nm and 570–630 nm respectively. Other detailed exposure conditions were as follows: Exposure Time: 60.0 sec; X-binning: 2× Binning; Y-binning: 2× Binning; f-Stop: 2.50; FOV: 180 mm; Focal Plane: 13.0 mm. The mice were anesthetized before and during imaging. The RFP signal intensity was quantified by using a molecular imaging software package (Carestream Health, USA). For patch characterization by RFP plasmid expression, presented fluorescent data are the average of two or three independent assays. Each data is showed as the mean ± standard deviation.
In vivo imaging system fx pro
Manufactured by Carestream
Sourced in United States
The In-Vivo Imaging System FX Pro is a laboratory equipment used for non-invasive, real-time imaging of small animals. It utilizes advanced imaging technologies to capture high-resolution images and data.
Automatically generated - may contain errors
Lab products found in correlation
Image suite software, by Carestream (2 mentions)
Molecular imaging software package, by Carestream (1 mentions)
Cy5 dye, by Cytiva (1 mentions)
Dcfh da, by Beyotime (1 mentions)
Cryomicrotome, by Leica (1 mentions)
Mi se software, by Carestream (1 mentions)
Balb c mice, by Inotiv (1 mentions)
Nitrocellulose membrane, by Cytiva (1 mentions)
Goat anti rabbit igg, by Santa Cruz Biotechnology (1 mentions)
Mouse anti gfap, by Merck Group (1 mentions)
Rabbit anti cx43, by Merck Group (1 mentions)
Horseradish peroxidase conjugated donkey anti goat igg, by Santa Cruz Biotechnology (1 mentions)
Goat anti aqp4, by Santa Cruz Biotechnology (1 mentions)
Immobilon western chemiluminescent hrp substrate, by Merck Group (1 mentions)
Apr 004, by Alomone (1 mentions)
A1978, by Merck Group (1 mentions)
Immobilon western detection kit, by Merck Group (1 mentions)
Phenyl methyl sulfonyl fluoride (pmsf), by Merck Group (1 mentions)
Protease inhibitor, by Roche (1 mentions)
26 protocols using in vivo imaging system fx pro
1
In Vivo RFP Expression Monitoring
2
In Vivo Fluorescence Imaging of Gastric Lymph Nodes
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In this experiment, we conjugated DIONs with Cy5 dye (Amersham Pharmacia Biotech UK Ltd. Locations, Little Chalfont, UK). The resultant DIONs were abbreviated as DIONs-Cy5. DIONs-Cy5 were prepared through Cy5-dextrans, and were prepared in a similar way to a previously described protocol.19 (link) Near-infrared dye Cy5 was applied as the fluorescent probe. Then, 75 mg/mL DIONs-Cy5 was injected into 4 rats’ gastric submucosal layers at 5 points (0.05 mL per point). After the operation, the animals were sacrificed at 6, 12, 24 and 48 h; perigastric LNs and major organs, including gastric organs and the liver, kidney, lung, spleen and heart, were excised and imaged with a small animal in vivo fluorescence imaging system (Carestream In-Vivo Imaging System FXPRO; Carestream Health, Inc., Woodbridge, CT, USA). This experiment was repeated 3 times.
3
Intranasal Delivery of PLGA, TMC, and Lf-TMC Nanoparticles
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
KM mice were randomized into three groups and treated intranasally with DiR-loaded PLGA, TMC, or Lf-TMC NPs. Three mice for each formulation per time-point (0.5, 1, 4, and 8 h) were used in the study. For intranasal administration of NPs, a capillary-end gel-loading pipette tip (Corning Inc., Corning, NY, USA) attached to a pipette containing a DiR dose of 0.5 mg/kg was inserted approximately 10 mm into the mouse nasal cavity. The live mice were monitored at various time-points, and images of organs were obtained at the final time-point using the In-Vivo Imaging System FX Pro (Carestream, NY, USA) with an excitation wavelength of 720 nm and emission wavelength of 790 nm. Before administration and imaging, mice were anesthetized by intraperitoneal injection of chloral hydrate. The images were analyzed using Carestream Image Suite Software.
4
Oral Delivery of Fc-targeted NPs
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Dir, a hydrophobic fluorescence label, was encapsulated into PEG-PLGA NPs and Fc-PEG-PLGA NPs. The NPs were administered orally to mice at a Dir dose of 0.25 mg/kg to investigate the Fc targeting effects using in vivo imaging in live mice. Living mice were monitored at 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h after administration and organ images were obtained at the 2, 6, 12, and 24 h time points using the In-Vivo Imaging System FX Pro (Carestream, NY, USA) with an excitation wavelength of 720 nm and an emission wavelength of 790 nm. The images were analyzed using Carestream Image Suite Software38 (link).
5
In Vivo Nanoparticle Biodistribution Imaging
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In vivo fluorescence imaging was performed to investigate the biodistribution of nanoparticles in HepG2/DOX tumor-bearing mice. After the tumor reached about 400 mm3, mice were injected intravenously with the near-infrared fluorescence probe-cy5.5-labeled nanoparticles. The fluorescence was recorded with a small animal in vivo fluorescence imaging system (In-Vivo Imaging System FX Pro, Carestream Health, Inc., New Haven, CT, USA) at the excitation wavelength of 670 nm.
6
In Vivo Evaluation of Periodontal ROS
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Four days after the last therapy, the rats were anesthetized and depilated, followed by a subgingival injection of DCFH-DA (Beyotime, China) to evaluate the ROS levels in periodontal pockets [31 (link)]. A living small animal imaging system (Carestream InVivo Imaging System FX PRO, USA) was used for fluorescence imaging of the rats, as well as quantification of the fluorescence intensity (510 nm excitation filter; 600 nm emission filter).
7
Quantifying Thoracic Vertebral Deformation in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Before sacrifice for collection of tissue samples, mice were anesthetized with 0.01/100mg Ketamine® and Xylazine® (4:1) by intraperitoneal route, and fixed in lateral decubitus with the aid of adhesive tape. Digital radiographic images were obtained with the In-vivo Imaging System FX PRO (Carestream Molecular Imaging). To assess the severity of the thoracic vertebra deformation, Kyphosis Index Ratio (KI) was used [7 (link),8 (link)]. Briefly, KI is the ratio between the length of a straight line from the last cervical vertebra to the sixth lumbar vertebra and the length of a line perpendicular to the latter, from the dorsal edge of the vertebra at the point of greatest curvature to the first line.
8
Targeted Gene Delivery with S-LCP Nanoparticles
9
In Vivo Imaging of GA-Loaded DiR Liposomes
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The DiR liposomes containing DSPE-PEG (PEG-DiR-Lip) and mediated by different GA derivatives (18β-GA-DiR-Lip, 18α-GA-DiR-Lip, 3-Ace-GA-DiR-Lip and 11-Deo-GA-DiR-Lip) were prepared according to the previously mentioned method. Male BALB/c mice were inoculated subcutaneously in the right axillary fossa with 0.2 mL of H22 cell suspension (2×106 cells/mL). Once the tumor reached a volume of 150–200 mm3, the H22 tumor-bearing mice were obtained. The mice were divided into five groups and intravenously injected with 0.2 mL of various DiR liposomes. In the period of 12 h postinjection, the mice under anesthetic state were scanned using a Kodak In Vivo Imaging System FX Pro (Carestream Health Inc., Rochester, NY, USA) at different time.
10
In Vivo Xenograft Tumor Killing Assay
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female nude mice, 7–9 weeks of age, were housed in the Laboratory Animal Research Center of China Pharmaceutical University (CPU), and all protocols were performed as approved by the CPU Institutional Animal Care and Use Committee. To carry out the xenograft models, nude mice were randomly divided into six groups (n = 5) and were intravenously inoculated with 5 × 105 engineered tumor cells per mouse (day 0), including AsPC-1 cells, HT29 cells, U87 cells, or PANC-1 cells. After 7 days, 2 × 106 CAR-T cells or wild T cells per mouse were infused intravenously.
To characterize the tumor killing effect in vivo, tumor burden of each mouse was measured using the In-Vivo Imaging System Fx Pro (Carestream Health) following the instrument’s instructions at 7 days, 14 days, 21 days, 28 days, and 35 days after tumor injection. In this experiment, the cytotoxicity of modified T cells was calculated according to the radiance intensity in the region of the tumor site. Finally, a ratio of the mean fluorescence intensity (MFI) of tumor cells in the mice treated with engineered T cells to that of the mice treated with wild T cells (No CAR T) was calculated to enumerate redirected cytotoxic activities of engineered T cells at 35 days after tumor injection.
To characterize the tumor killing effect in vivo, tumor burden of each mouse was measured using the In-Vivo Imaging System Fx Pro (Carestream Health) following the instrument’s instructions at 7 days, 14 days, 21 days, 28 days, and 35 days after tumor injection. In this experiment, the cytotoxicity of modified T cells was calculated according to the radiance intensity in the region of the tumor site. Finally, a ratio of the mean fluorescence intensity (MFI) of tumor cells in the mice treated with engineered T cells to that of the mice treated with wild T cells (No CAR T) was calculated to enumerate redirected cytotoxic activities of engineered T cells at 35 days after tumor injection.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!